CYP2C19 polymorphism influences Helicobacter pylori eradication - Test2 - elhamkhani - TriplyDB

CYP2C19 polymorphism influences Helicobacter pylori eradication

CYP2C19 polymorphism influences Helicobacter pylori eradication

http://www.wikidata.org/entity/Q27005916

about

Treatment of Helicobacter pylori infection: Current and future insights Antibiotic treatment for Helicobacter pylori: Is the end coming?Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance.Effect of CYP2C19 Gene Polymorphisms on Proton Pump Inhibitor, Amoxicillin, and Levofloxacin Triple Therapy for Eradication of Helicobacter Pylori Gastric Juice-Based Real-Time PCR for Tailored Helicobacter Pylori Treatment: A Practical Approach.Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection A Rapid and Accurate Method to Evaluate Helicobacter pylori Infection, Clarithromycin Resistance, and CYP2C19 Genotypes Simultaneously From Gastric Juice Treatment of Helicobacter Pylori infection: optimization strategies in a high resistance era.The internalization of Helicobacter pylori plays a role in the failure of H. pylori eradication.Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions.Microarray-Based Detection and Clinical Evaluation for Resistance to Clarithromycin or Levofloxacin and the Genotype of CYP2C19 in 1083 Patients

P2860

Q26769707-AFBEAD8B-2523-4B31-9517-6CD6B6F71F0C Q26777623-769A5521-A41D-4EF0-9B99-AECF764DF2AF Q33639114-4EEB84A8-8EF1-48DF-BE57-6F10AB5B9A22 Q33787853-BDDA0A51-A99F-4E71-90C6-32653C85DA5D Q33820650-C4CC0C0E-9416-4E40-B62E-883A9D363D5C Q36360839-AF367583-F08D-4A47-BCC9-2E619F8BAD1C Q36992812-AF820949-1CA3-471E-B0C2-8D0295529276 Q38578674-533661CD-4255-4156-9BAE-0C74273C4581 Q38765449-1D13E3AC-534D-484C-AE02-901EC186A0DA Q52614686-43E9DE0A-2E82-46D8-945A-BCC305A7C579 Q57114157-2FF2F99B-E7F6-402C-AAD1-6167987B870C

P2860

CYP2C19 polymorphism influences Helicobacter pylori eradication

http://www.wikidata.org/entity/Q27005916

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

CYP2C19 polymorphism influences Helicobacter pylori eradication

@ast

CYP2C19 polymorphism influences Helicobacter pylori eradication

@en

CYP2C19 polymorphism influences Helicobacter pylori eradication

@nl

type

label

CYP2C19 polymorphism influences Helicobacter pylori eradication

@ast

CYP2C19 polymorphism influences Helicobacter pylori eradication

@en

CYP2C19 polymorphism influences Helicobacter pylori eradication

@nl

prefLabel

CYP2C19 polymorphism influences Helicobacter pylori eradication

@ast

CYP2C19 polymorphism influences Helicobacter pylori eradication

@en

CYP2C19 polymorphism influences Helicobacter pylori eradication

@nl

P1433

Q27005916-66A23B1D-B627-4030-8432-CD2021F09565

P1476

Q27005916-7FFD9EF9-E8A5-4B16-BF6E-F6A99E593F2A

P2093

Q27005916-0B3AFE8D-3494-4406-8419-DC9989ED2A65

Q27005916-0BD165CF-EA93-4C9D-9A6F-A32033BCF2CE

Q27005916-1AE76160-34BF-4EF5-A870-EEE9E2FB5B2E

Q27005916-223B7DC4-84ED-43AD-AD4C-2247D374C1AC

Q27005916-2801FF10-BA4E-4DE5-B49C-35532798916C

Q27005916-87FB3989-5D9C-44DE-90A3-7CE83761FAEB

Q27005916-9EC6C78D-123D-4882-BAFA-D10351BF29B7

Q27005916-C69439CD-C1D9-4861-947B-88976DD400E0

Q27005916-D5A98083-9B3E-4945-B9F9-723CD1992D42

P2860

Q27005916-1631576B-52E8-431B-B315-F6FB9ABB3749

Q27005916-18144E15-7B46-4F33-83A1-A3E0B4E8EF59

Q27005916-2114FB67-871A-41FB-BEB0-40F1DE1559D7

Q27005916-2676D7B4-DAF9-480E-933F-C20DACB3A444

Q27005916-293D0EE7-1D9D-4A6C-BB39-30EC4DFD8E74

Q27005916-3959796A-CE03-4A64-8AC2-816C40E91A29

Q27005916-4078CEEE-8F1D-4884-A5D0-0A3B253FFE7B

Q27005916-45F62C53-4CCA-4425-9D35-DBF7A81D3185

Q27005916-5265A0EE-F805-407B-9909-7B8B50F5D9D0

Q27005916-52A666C2-8C8E-40F2-A50B-7A3B81AAD5DE

P304

Q27005916-DF754AFC-868E-4273-85CC-4C39D99C3726

P31

Q27005916-3924B07E-63D7-4771-BE07-A7EDB2DD8265

P3181

Q27005916-567BC236-8DAA-4742-BF8E-7B7D285436F7

P356

Q27005916-EF7A19B2-1242-46B7-9F74-727ADDA6F645

P407

Q27005916-C60CFDA3-20F6-4C61-A99D-03C0D583AD9E

P433

Q27005916-8853C5AF-B4C5-4A9C-8C1A-FD81E130A886

P478

Q27005916-A1E46163-7DC9-4B89-9A38-4F1F9D9C1FB9

P50

Q27005916-DCACD632-199B-4FD4-B42A-82A8B40BAA69

P577

Q27005916-8346B9FC-1BB7-4254-9623-2567B857BDD0

P698

Q27005916-F5C33FCA-71D8-49CA-A842-45A9AD1413A1

P921

Q27005916-543C5320-1B1B-4D07-BDA9-00F5A33E7B3A

P932

Q27005916-439FB666-EBCE-4C0C-A0D0-B8A16AE3F849

P3181

P356

WJG.V20.I43.16029

P1433

World Journal of Gastroenterology

P1476

CYP2C19 polymorphism influences Helicobacter pylori eradication

@en

P2093

Chao-Hung Kuo

http://www.w3.org/2001/XMLSchema#string

Chien-Yu Lu

http://www.w3.org/2001/XMLSchema#string

Deng-Chyang Wu

http://www.w3.org/2001/XMLSchema#string

Fang-Jung Yu

http://www.w3.org/2001/XMLSchema#string

Fu-Chen Kuo

http://www.w3.org/2001/XMLSchema#string

Hsiang-Yao Shih

http://www.w3.org/2001/XMLSchema#string

Huang-Ming Hu

http://www.w3.org/2001/XMLSchema#string

Meng-Chieh Wu

http://www.w3.org/2001/XMLSchema#string

Wen-Hung Hsu

http://www.w3.org/2001/XMLSchema#string

P2860

Interleukin-1 polymorphisms associated with increased risk of gastric cancer

Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese

Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.

Review article: the pharmacology of rabeprazole.

Review article: cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole.

Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin.

H+/K+-ATPase inhibitors: a patent review.

Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole.

Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.

P304

16029-16036

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1936431

http://www.w3.org/2001/XMLSchema#string

P356

10.3748/WJG.V20.I43.16029

http://www.w3.org/2001/XMLSchema#string

P407

P433

43

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-11-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25473155

http://www.w3.org/2001/XMLSchema#string

P921

Helicobacter pylori

P932

4239489

http://www.w3.org/2001/XMLSchema#string